Adjuvant chemotherapy for high-risk stage II and stage III colon cancer: timing of initiation and optimal duration

Jan Paolo M. Cruz, Chris George C. Pales, Kwang Min Kim, Young Wan Kim

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The benefit of adjuvant chemotherapy has been clearly proven for patients with stage III (node-positive) and high-risk stage II colon cancer and consists to eradicating micrometastases that may be present during the time of surgical resection, reducing thereby the likelihood of disease recurrence and potentially increasing the cure rates after surgery. In this review, the appropriate timing of initiation and optimal duration of adjuvant chemotherapy are discussed. Current guidelines recommend an oxaliplatin-based regimen (FOLFOX: 5-fluorouracil with oxaliplatin or CapeOx: capecitabine with oxaliplatin) instead of 5-FU/LV (5-fluorouracil/leucovorin) for 6 months. For patients with a contraindication to oxaliplatin, a fluoropyrimidine-based regimen alone is an acceptable option. It should be initiated within 6-8 weeks from the time of surgical resection. Studies on reduced duration of fluoropyrimidine-based only regimens (bolus 5-FU/LV vs 5-FU) showed no significant difference in overall (OS) and disease free survival (DFS) benefits. However, the studies showed significantly lower toxicities for protracted venous infusion (PVI) 5-FU given for shorter duration. For oxaliplatin-based therapies, prospective trials failed to establish non-inferiority of 3 months compared to 6 months of oxaliplatin-based adjuvant therapy. The long-term data of the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) collaboration for OS are not mature to date yet. Six months of oxaliplatin-based therapy still remain the standard of care. Decisions to shorten the duration of adjuvant oxaliplatin-based therapy should be dictated by drug tolerability, risk stratification of the disease, consideration of the value of decreased neurotoxicity at the cost of decreased DFS, and patient preference.

Original languageEnglish
Pages (from-to)568-573
Number of pages6
JournalJournal of B.U.ON.
Volume23
Issue number3
Publication statusPublished - 2018 May 1

Fingerprint

oxaliplatin
Adjuvant Chemotherapy
Colonic Neoplasms
Fluorouracil
Leucovorin
Disease-Free Survival
Neoplasm Micrometastasis
Cost of Illness
Patient Preference
Therapeutics
Standard of Care

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Cruz, Jan Paolo M. ; Pales, Chris George C. ; Kim, Kwang Min ; Kim, Young Wan. / Adjuvant chemotherapy for high-risk stage II and stage III colon cancer : timing of initiation and optimal duration. In: Journal of B.U.ON. 2018 ; Vol. 23, No. 3. pp. 568-573.
@article{9a948b52fcb14475b6191c9810debad3,
title = "Adjuvant chemotherapy for high-risk stage II and stage III colon cancer: timing of initiation and optimal duration",
abstract = "The benefit of adjuvant chemotherapy has been clearly proven for patients with stage III (node-positive) and high-risk stage II colon cancer and consists to eradicating micrometastases that may be present during the time of surgical resection, reducing thereby the likelihood of disease recurrence and potentially increasing the cure rates after surgery. In this review, the appropriate timing of initiation and optimal duration of adjuvant chemotherapy are discussed. Current guidelines recommend an oxaliplatin-based regimen (FOLFOX: 5-fluorouracil with oxaliplatin or CapeOx: capecitabine with oxaliplatin) instead of 5-FU/LV (5-fluorouracil/leucovorin) for 6 months. For patients with a contraindication to oxaliplatin, a fluoropyrimidine-based regimen alone is an acceptable option. It should be initiated within 6-8 weeks from the time of surgical resection. Studies on reduced duration of fluoropyrimidine-based only regimens (bolus 5-FU/LV vs 5-FU) showed no significant difference in overall (OS) and disease free survival (DFS) benefits. However, the studies showed significantly lower toxicities for protracted venous infusion (PVI) 5-FU given for shorter duration. For oxaliplatin-based therapies, prospective trials failed to establish non-inferiority of 3 months compared to 6 months of oxaliplatin-based adjuvant therapy. The long-term data of the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) collaboration for OS are not mature to date yet. Six months of oxaliplatin-based therapy still remain the standard of care. Decisions to shorten the duration of adjuvant oxaliplatin-based therapy should be dictated by drug tolerability, risk stratification of the disease, consideration of the value of decreased neurotoxicity at the cost of decreased DFS, and patient preference.",
author = "Cruz, {Jan Paolo M.} and Pales, {Chris George C.} and Kim, {Kwang Min} and Kim, {Young Wan}",
year = "2018",
month = "5",
day = "1",
language = "English",
volume = "23",
pages = "568--573",
journal = "Journal of B.U.ON.",
issn = "1107-0625",
publisher = "Balkan Union of Oncology",
number = "3",

}

Adjuvant chemotherapy for high-risk stage II and stage III colon cancer : timing of initiation and optimal duration. / Cruz, Jan Paolo M.; Pales, Chris George C.; Kim, Kwang Min; Kim, Young Wan.

In: Journal of B.U.ON., Vol. 23, No. 3, 01.05.2018, p. 568-573.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Adjuvant chemotherapy for high-risk stage II and stage III colon cancer

T2 - timing of initiation and optimal duration

AU - Cruz, Jan Paolo M.

AU - Pales, Chris George C.

AU - Kim, Kwang Min

AU - Kim, Young Wan

PY - 2018/5/1

Y1 - 2018/5/1

N2 - The benefit of adjuvant chemotherapy has been clearly proven for patients with stage III (node-positive) and high-risk stage II colon cancer and consists to eradicating micrometastases that may be present during the time of surgical resection, reducing thereby the likelihood of disease recurrence and potentially increasing the cure rates after surgery. In this review, the appropriate timing of initiation and optimal duration of adjuvant chemotherapy are discussed. Current guidelines recommend an oxaliplatin-based regimen (FOLFOX: 5-fluorouracil with oxaliplatin or CapeOx: capecitabine with oxaliplatin) instead of 5-FU/LV (5-fluorouracil/leucovorin) for 6 months. For patients with a contraindication to oxaliplatin, a fluoropyrimidine-based regimen alone is an acceptable option. It should be initiated within 6-8 weeks from the time of surgical resection. Studies on reduced duration of fluoropyrimidine-based only regimens (bolus 5-FU/LV vs 5-FU) showed no significant difference in overall (OS) and disease free survival (DFS) benefits. However, the studies showed significantly lower toxicities for protracted venous infusion (PVI) 5-FU given for shorter duration. For oxaliplatin-based therapies, prospective trials failed to establish non-inferiority of 3 months compared to 6 months of oxaliplatin-based adjuvant therapy. The long-term data of the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) collaboration for OS are not mature to date yet. Six months of oxaliplatin-based therapy still remain the standard of care. Decisions to shorten the duration of adjuvant oxaliplatin-based therapy should be dictated by drug tolerability, risk stratification of the disease, consideration of the value of decreased neurotoxicity at the cost of decreased DFS, and patient preference.

AB - The benefit of adjuvant chemotherapy has been clearly proven for patients with stage III (node-positive) and high-risk stage II colon cancer and consists to eradicating micrometastases that may be present during the time of surgical resection, reducing thereby the likelihood of disease recurrence and potentially increasing the cure rates after surgery. In this review, the appropriate timing of initiation and optimal duration of adjuvant chemotherapy are discussed. Current guidelines recommend an oxaliplatin-based regimen (FOLFOX: 5-fluorouracil with oxaliplatin or CapeOx: capecitabine with oxaliplatin) instead of 5-FU/LV (5-fluorouracil/leucovorin) for 6 months. For patients with a contraindication to oxaliplatin, a fluoropyrimidine-based regimen alone is an acceptable option. It should be initiated within 6-8 weeks from the time of surgical resection. Studies on reduced duration of fluoropyrimidine-based only regimens (bolus 5-FU/LV vs 5-FU) showed no significant difference in overall (OS) and disease free survival (DFS) benefits. However, the studies showed significantly lower toxicities for protracted venous infusion (PVI) 5-FU given for shorter duration. For oxaliplatin-based therapies, prospective trials failed to establish non-inferiority of 3 months compared to 6 months of oxaliplatin-based adjuvant therapy. The long-term data of the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) collaboration for OS are not mature to date yet. Six months of oxaliplatin-based therapy still remain the standard of care. Decisions to shorten the duration of adjuvant oxaliplatin-based therapy should be dictated by drug tolerability, risk stratification of the disease, consideration of the value of decreased neurotoxicity at the cost of decreased DFS, and patient preference.

UR - http://www.scopus.com/inward/record.url?scp=85049457315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049457315&partnerID=8YFLogxK

M3 - Review article

C2 - 30003720

AN - SCOPUS:85049457315

VL - 23

SP - 568

EP - 573

JO - Journal of B.U.ON.

JF - Journal of B.U.ON.

SN - 1107-0625

IS - 3

ER -